A VUS on Your Genetic Test: What to Record and Ask Next

A variant of uncertain significance, or VUS, is a genetic finding whose connection to disease cannot currently be established. NHGRI explains that more evidence is needed to determine whether such a variant is related to a health condition. Uncertainty describes the interpretation of this finding; it does not establish that you have a genetic disease.

It also does not mean that the variant has been classified as benign, or that the whole test can be summarized as negative. Ask the ordering clinician or genetic counselor to explain this particular result alongside the reason for testing. A report can contain other findings or limitations that need separate discussion.

This guide concerns a clinically issued germline report used to assess a genetic condition or inherited risk. Check the test type with the ordering service if it is unclear. Do not infer from the word ‘genetic’ that every report answers the same question, or from ‘germline’ that the finding has been shown to come from a particular relative.

NCI distinguishes inherited-cancer testing from tumor testing, which looks for changes in cancer cells and may help guide cancer treatment. Tumor testing can sometimes identify inherited changes, but does not replace inherited-risk assessment. A tumor-only VUS therefore needs its oncology and laboratory context. Consumer raw-data interpretations, carrier screening and prenatal or reproductive decisions also require their own professional discussion.

Keep a complete copy with the laboratory, test name, ordering clinician, report date and any version or amendment date. Copy the reported gene and variant designation exactly. If the notation is difficult to read, leave it attached for the genetics team rather than shortening it or guessing what its letters and numbers mean.

Identify which finding you want explained and whether the clinician has the same report version. Ask what was examined, what the report's limitations mean for your question, and whether another result needs separate attention. An online gene description or a different person's variant is not an interpretation of your report.

The ACMG/AMP foundational classification guidance says a VUS should not be used for clinical decision-making. Do not select medicine changes, extra screening, preventive surgery or other procedures from this finding. Equally, do not cancel an existing clinical plan because the report has not established a genetic cause.

The NHS Genomics Education Programme explains that care in this situation can still depend on personal and family history. Ask which clinical information supports your current plan and which question remains unresolved. An uncertain genetic finding does not erase symptoms, an existing diagnosis or a family-history concern, and it does not provide a personal risk estimate.

Ask for a short written summary stating the report's meaning today, the reason for the current plan and which question a later review would address.

Share relevant existing family information, marking unknown or reported details accurately. You do not need to build a complete family tree before discussing the result. The separate family-history guide can help organize missing details without turning them into a negative history.

NHS genomics guidance distinguishes specialist-selected studies of relatives to gather classification evidence from predictive testing used to guide relatives' care. Do not arrange family genetic testing from a VUS designation yourself. If the team mentions family studies, ask what question they would answer, whose participation would be useful, and what consent and explanation would be provided. No particular relative's participation is assumed here.

A classification may change when additional evidence becomes available, but some variants remain uncertain. New information can come from research, population information or clinical evidence. You cannot predict a future classification from the fact that a VUS was reported, and no update is a promise that the uncertainty will be resolved.

ACMG's reanalysis guidance distinguishes reviewing a previously reported variant from a broader review of existing genomic data. Collecting a new sample or ordering another test is a separate decision. Ask which process the team is discussing, what it could clarify and whether it is appropriate here. None is automatically required because the report contains a VUS.

Ask how the laboratory and clinical service handle reinterpretation requests and amended reports. The ACMG reanalysis statement discusses laboratory policies, resources and possible charges; it does not promise continuous review of every result. Ask whether a request must come through a clinician, what information is needed and whether any fee or additional consent applies.

Clarify who would receive an amended report and who would explain it to you. Ask what happens if the original clinician moves or you change services. Keep your contact details current and record any agreed review date or trigger. Do not assume there is a universal interval, automatic notification or a guaranteed update simply because the laboratory has your result.

Use this original worksheet with the full report. It is a communication aid, not a variant-interpretation tool or an official genetics form. Leave fields unknown until the service clarifies them.

• Testing reason and ordering clinician/service: ___; laboratory and test name: ___; germline / tumor-only / unclear: ___.
• Report date/version and amendment date, if any: ___; original stored privately at: ___; clinician has this version: ___.
• Exact gene and variant designation copied from report: ___; exact classification wording and any stated limitations: ___.
• Finding discussed today: ___; other findings needing explanation: ___; what this result does not establish: ___.
• Current clinical plan and the personal/family evidence the clinician says supports it: ___; unresolved question: ___.
• Further evidence or review discussed, purpose and responsible professional: ___ / none agreed; no self-selected family testing.
• Update-request route, required information, fees/consent to clarify: ___; amended-report recipient and person explaining it: ___.
• Agreed contact/review trigger or date: ___; contact if ordering clinician changes: ___; date details checked or report updated: ___.

ACMG announced a new statement in 2026 on reporting and communicating germline VUS to laboratories and healthcare professionals. The publication of reporting guidance does not mean your own report has been reassessed. If unfamiliar classification wording appears, ask the genetics team what it means in that report and whether an amended clinical explanation is needed.

Tell your usual clinician about new symptoms or changes in health rather than waiting for a future genetics update. Ask the genetics service how to share a new diagnosis or relevant family information. If uncertainty is distressing, say which unanswered question is troubling you and ask for a clear explanation of what is known today.

Use the service's approved private route for genetic reports and family information. Avoid public uploads or assuming that removing your name makes a family-linked report anonymous. Keep later reports with their dates and ask the clinician to explain whether an amendment affects any advice. The written plan should show both the current understanding and what remains uncertain.